Sponsored by
Gliadel has been approved since 1996 for recurrent glioblastoma and in 2003 for newly diagnosed glioblastoma. They are biodegradable wafers implanted into the resection cavity at the time of a brain tumor surgery, and slowly release BCNU chemotherapy This new study shows remarkable results in the worst subgroup of patients - those over 80 years old with a slow karnofsky score. Survival was improved from 16.5 months to 39 months, with no additional side effects (beyond what the surgery usually causes).